Answers are grounded in this paper and cite their sources.
This research is conducted to increase the therapeutic efficacy of the commonly used anticancer drug doxorubicin (DRN), commonly called Adriamycin. The most popular mechanisms of DRN are inhibiting the topoisomerase-II enzyme and forming a complex with DNA. A major challenge in the use of this drug is severe cardiotoxicity, immunotoxicity, and the development of multidrug resistance. Nanotechnology is applied to overcome all these problems. This research is conducted with the idea to incorporate DRN in chitosan nanoparticles (NPs). DRN was found to have the highest solubility in water and max was found to be 232 nm. Major FTIR peaks of chitosan, STTP, pure DRN, physical mixture of chitosan-STTP, and physical mixture of DRN-chitosan-STTP represented their respective functional groups in each spectrum. To optimize the concentration of chitosan, STTP, and DRN for preparing NPs, a range of plain chitosan NPs (PLN-CNPs) and DRN loaded chitosan NPs (DRN-CNPs) are prepared. The polydispersity index (PDI), particle size, zeta potential, and electrophoretic mobility mean (EMM) is measured for all these formulations. Pareto analysis of particle size and PDI showed PLN-CNPs-3 and DRN-CNPs-1 as the best formulations for further studies. FTIR analysis of PLN-CNPs-3 and DRN-CNPs-1 showed the functional groups which represent cross linking of chitosan and STTP and incorporation of DRN in NPs, respectively. SEM analysis showed the particle size as 172 nm and 174 nm for PLN-CNPs-3 and DRN-CNPs-1 NPs. DRN-CNPs are further evaluated for release of the drug, encapsulation, and loading efficiency. After 60 h, more than 50% of the drug was released from the formulation. Encapsulation efficiency, loading efficiency, and % yield of DRN-CNPs-1 were found to be 78.5%, 13.8%, and 35.7%, respectively. Debye-Scherrer equation was applied for 2 peaks obtained from XRD data of DRN-CNPs-1 to calculate average particle size (30.50 nm). Anticancer activity of DRN-CNPs-1 was compared with unloaded DRN against MCF-7 cell lines. It was dose dependent in both treatments and DRN-CNPs-1 was found to be more effective than DRN. This research put forth an idea to use chitosan a biocompatible polymer for loading anticancer drugs like DRN to increase their efficacy.
No takes yet. Share an insight, caveat, or question.
Uddin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: